As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Ozempic and other GLP-1 drugs like it have become so pervasive in the zeitgeist that it’s likely even your most social ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.
Injectable drugs like Ozempic and Wegovy may be new to most of the world, but the science behind them are familiar to those in the health field.
Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Whether it’s Ozempic, Pilates, or sheer will, celebrity transformations take all shapes and sizes - so what's the hassle all ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results